Researchers discovered that the enzyme TYK2 alters the tau protein, promoting its accumulation in the brain, a process linked ...

Researchers at Baylor College of Medicine, the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas ...

TYK2 enzyme changes tau protein from a protective role to a harmful one, contributing to Alzheimer’s disease progression.

Scientists have discovered that the enzyme TYK2 modifies tau proteins, leading to their accumulation in the brain—a key ...

The JAK3/TYK2 inhibitor ritlecitinib received FDA approval for this indication in 2023; brepocitinib, a TYK2/JAK1 inhibitor, ...

Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...

Researchers at Baylor College of Medicine, the Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital and collaborating institutions discovered that the enzyme ...

Alumis Inc. (ALMS) has received a new Buy rating, initiated by Robert W. Baird analyst, Brian Skorney. Brian Skorney has given his Buy rating ...

Another drug with a known mechanism of action, in the area of autoimmune diseases, is BHV-8000, a TYK2/JAK1 inhibitor in ...

Biogen Inc. has identified non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, autoimmune disease, cardiovascular disorders, fibrosis, inflammatory ...

Innocare Pharma Ltd.’s tyrosine kinase 2 (TYK2) inhibitor, ICP-488, met the primary endpoint in a phase II trial in Chinese patients with moderate to severe plaque psoriasis, and the results clear the ...

Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, ...